DK1575590T3 - Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser - Google Patents

Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser

Info

Publication number
DK1575590T3
DK1575590T3 DK03786308T DK03786308T DK1575590T3 DK 1575590 T3 DK1575590 T3 DK 1575590T3 DK 03786308 T DK03786308 T DK 03786308T DK 03786308 T DK03786308 T DK 03786308T DK 1575590 T3 DK1575590 T3 DK 1575590T3
Authority
DK
Denmark
Prior art keywords
serotonin reuptake
reuptake inhibitors
mood disorders
carbostyril derivatives
treat mood
Prior art date
Application number
DK03786308T
Other languages
English (en)
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1575590(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK1575590T3 publication Critical patent/DK1575590T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DK03786308T 2002-12-27 2003-12-25 Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser DK1575590T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27
US47048103P 2003-05-14 2003-05-14
PCT/JP2003/016724 WO2004060374A1 (en) 2002-12-27 2003-12-25 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Publications (1)

Publication Number Publication Date
DK1575590T3 true DK1575590T3 (da) 2008-02-11

Family

ID=32716306

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03786308T DK1575590T3 (da) 2002-12-27 2003-12-25 Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser

Country Status (27)

Country Link
US (5) US9387182B2 (da)
EP (2) EP1575590B1 (da)
JP (1) JP4284524B2 (da)
KR (2) KR100842694B1 (da)
CN (2) CN1726039B (da)
AT (1) ATE376419T1 (da)
AU (1) AU2003295235B2 (da)
BR (1) BR0317771A (da)
CA (1) CA2511619C (da)
CY (1) CY1108060T1 (da)
DE (1) DE60317098T2 (da)
DK (1) DK1575590T3 (da)
EC (1) ECSP055885A (da)
ES (1) ES2295677T3 (da)
HK (3) HK1082411A1 (da)
IL (1) IL169358A (da)
MX (1) MXPA05006857A (da)
MY (1) MY152919A (da)
NO (1) NO333291B1 (da)
NZ (2) NZ556779A (da)
PE (1) PE20040923A1 (da)
PL (1) PL211975B1 (da)
PT (1) PT1575590E (da)
RU (2) RU2356554C2 (da)
SI (1) SI1575590T1 (da)
WO (1) WO2004060374A1 (da)
ZA (1) ZA200503873B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102172402A (zh) * 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US20090198059A1 (en) * 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
US8729120B2 (en) 2004-10-28 2014-05-20 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
TWI636784B (zh) 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2868319A4 (en) 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) * 2018-05-03 2020-07-28 杭州端丽生物技术有限公司 化合物fty720在制备治疗行为和运动异常检测标记物中的应用
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
EP3970710A4 (en) 2019-05-13 2023-06-14 VASTHERA Co. Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES BY ACTIVATION OF AUTOPHAGY
KR20200132730A (ko) 2019-05-15 2020-11-25 연세대학교 산학협력단 오토파지 활성화제를 유효성분으로 포함하는 심뇌혈관 질환의 예방 또는 치료용 조성물
US11080484B1 (en) * 2020-10-08 2021-08-03 Omniscient Neurotechnology Pty Limited Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
HUP9903684A3 (en) 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EA000976B1 (ru) 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
JP2001520195A (ja) 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
CA2601132C (en) 1998-04-14 2011-11-08 The General Hospital Corporation Use of n-methylglycine and pharmaceutical compositions comprising n-methylglycine for treating neuropsychiatric disorders
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
DE69922367T2 (de) 1998-05-08 2005-12-22 Pharmacia & Upjohn Co., Kalamazoo Neue arzneimittelkombinationen aus reboxetin und pindolol
AU3891299A (en) 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911049A (pt) 1998-05-22 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de depressão resistente
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
IL139591A0 (en) 1998-05-29 2002-02-10 Lilly Co Eli Combination therapy for treatment of bipolar disorders
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JP2002530340A (ja) 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
EP1165090A2 (en) 1999-03-18 2002-01-02 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
AU4062900A (en) 1999-04-06 2000-10-23 Sepracor, Inc. Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
WO2002053140A2 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072145A1 (fr) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
GEP20053545B (en) 2001-04-19 2005-06-10 Warner Lambert Co Fused Bicyclic or Tricyclic Amino Acids
JP2004527553A (ja) 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
EP1480629A1 (en) 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003101492A2 (en) 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
EP1545618A1 (en) 2002-07-29 2005-06-29 Potomac, Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003301762B2 (en) 2002-10-25 2006-02-09 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CN102172402A (zh) 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
MXPA06002778A (es) 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
US20050250803A1 (en) 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

Also Published As

Publication number Publication date
ZA200503873B (en) 2006-08-30
EP1575590B1 (en) 2007-10-24
CN1989968B (zh) 2011-05-11
EP1575590A1 (en) 2005-09-21
BR0317771A (pt) 2005-11-22
SI1575590T1 (sl) 2008-04-30
RU2389490C2 (ru) 2010-05-20
AU2003295235A1 (en) 2004-07-29
PT1575590E (pt) 2007-12-06
PE20040923A1 (es) 2005-01-22
ECSP055885A (es) 2005-11-22
PL211975B1 (pl) 2012-07-31
KR20070093001A (ko) 2007-09-14
CY1108060T1 (el) 2014-02-12
CN1726039B (zh) 2010-08-18
CN1989968A (zh) 2007-07-04
ATE376419T1 (de) 2007-11-15
CN1726039A (zh) 2006-01-25
EP1723957A2 (en) 2006-11-22
KR100858852B1 (ko) 2008-09-17
KR100842694B1 (ko) 2008-07-01
US20200289501A1 (en) 2020-09-17
US20190151308A1 (en) 2019-05-23
NO20052359L (no) 2005-07-18
RU2005123808A (ru) 2006-02-20
PL378214A1 (pl) 2006-03-20
CA2511619C (en) 2011-07-12
RU2356554C2 (ru) 2009-05-27
US9694009B2 (en) 2017-07-04
MY152919A (en) 2014-12-15
DE60317098T2 (de) 2008-08-07
US20160310489A1 (en) 2016-10-27
AU2003295235B2 (en) 2008-06-19
ES2295677T3 (es) 2008-04-16
US20170258788A1 (en) 2017-09-14
HK1082411A1 (en) 2006-06-09
DE60317098D1 (de) 2007-12-06
NZ540054A (en) 2007-09-28
NO333291B1 (no) 2013-04-29
WO2004060374A1 (en) 2004-07-22
US20140221388A1 (en) 2014-08-07
RU2008131331A (ru) 2010-02-10
NZ556779A (en) 2008-12-24
MXPA05006857A (es) 2005-08-18
EP1723957A3 (en) 2013-01-23
JP4284524B2 (ja) 2009-06-24
JP2004217650A (ja) 2004-08-05
IL169358A0 (en) 2007-07-04
CA2511619A1 (en) 2004-07-22
US9387182B2 (en) 2016-07-12
IL169358A (en) 2013-04-30
NO20052359D0 (no) 2005-05-12
HK1101550A1 (en) 2007-10-18
HK1145291A1 (en) 2011-04-15
KR20050085906A (ko) 2005-08-29

Similar Documents

Publication Publication Date Title
NO20052359D0 (no) Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20034056D0 (no) Proliferative sykdommer
DK1954274T3 (da) Substituerede quinoloner og fremgangsmåder til anvendelse
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE502935T1 (de) C-met-proteinkinasehemmer
ATE328608T1 (de) Verfahren und zusammensetzungen mit kombinationen aus terfenadinmetaboliten und leukotrienhemmer
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
ME00030B (me) GABOKSADOL ZA LEČENJE DEPRESIJE l DRUGIH AFEKTIVNIH POREMEĆAJA